BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32942295)

  • 1. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
    Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
    J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma.
    Rudman Y; Duskin-Bitan H; Masri-Iraqi H; Akirov A; Shimon I
    Pituitary; 2022 Dec; 25(6):882-890. PubMed ID: 36036309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
    Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
    Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment.
    Ribeiro RS; Abucham J
    Eur J Endocrinol; 2009 Jul; 161(1):163-9. PubMed ID: 19359408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists.
    Al Dahmani KM; Almalki MH; Ekhzaimy A; Aziz F; Bashier A; Mahzari MM; Beshyah SA
    Pituitary; 2022 Aug; 25(4):658-666. PubMed ID: 35793046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
    George LD; Nicolau N; Scanlon MF; Davies JS
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):595-9. PubMed ID: 11106920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline.
    Walia R; Bhansali A; Dutta P; Khandelwal N; Sialy R; Bhadada S
    Indian J Med Res; 2011 Sep; 134(3):314-9. PubMed ID: 21985814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism.
    Stumpf MAM; Galliano SA; Bueno CBF; Glezer A
    Endocrine; 2024 Apr; ():. PubMed ID: 38578401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
    Tirosh A; Benbassat C; Shimon I
    Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy.
    Kim D; Ku CR; Kim K; Jung H; Lee EJ
    Eur J Endocrinol; 2020 Feb; 182(2):177-183. PubMed ID: 31770105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?
    Rudman Y; Duskin-Bitan H; Manisterski Y; Pertzov B; Akirov A; Masri-Iraqi H; Shimon I
    Clin Endocrinol (Oxf); 2021 Oct; 95(4):606-617. PubMed ID: 34160838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression.
    Shimon I; Benbassat C; Tzvetov G; Grozinsky-Glasberg S
    Pituitary; 2011 Mar; 14(1):11-5. PubMed ID: 20717729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
    Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Male prolactinomas presenting with normal testosterone levels.
    Shimon I; Benbassat C
    Pituitary; 2014 Jun; 17(3):246-50. PubMed ID: 23756784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macroprolactinoma-Induced Syndrome of Inappropriate Antidiuresis and Its Reversal with Dopamine Agonist Therapy.
    Schlegel A
    Lab Med; 2022 Sep; 53(5):537-539. PubMed ID: 35552737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Giant prolactinoma in Asian-Indians: A single-center experience from Western India.
    Kumar S; Memon SS; Lila AR; Sarathi V; Sehemby M; Karlekar M; Sankhe S; Thakkar H; Patil VA; Shah N; Bandgar T
    Ann Endocrinol (Paris); 2023 Dec; 84(6):711-718. PubMed ID: 37866429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined cabergoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency.
    Cesario F; Borretta G; Meineri I; Muratori M; Pizzocaro A; Beck-Peccoz P
    J Pediatr Endocrinol Metab; 1997; 10(2):231-6. PubMed ID: 9364359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
    Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
    Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.